RT Journal Article
SR Electronic
T1 SARS-CoV-2 Delta vaccine breakthrough transmissibility in Alachua, Florida
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.10.21266134
DO 10.1101/2021.11.10.21266134
A1 Magalis, Brittany Rife
A1 Rich, Shannan
A1 Tagliamonte, Massimiliano S
A1 Mavian, Carla
A1 Cash, Melanie N
A1 Riva, Alberto
A1 Marini, Simone
A1 Amador, David Moraga
A1 Zhang, Yanping
A1 Shapiro, Jerne
A1 Horine, Amelia
A1 Starostik, Petr
A1 Pieretti, Maura
A1 Vega, Samantha
A1 Lacombe, Ana Paula
A1 Salinas, Jessica
A1 Stevenson, Mario
A1 Myers, Paul
A1 Morris, J. Glenn
A1 Lauzardo, Michael
A1 Prosperi, Mattia
A1 Salemi, Marco
YR 2021
UL http://medrxiv.org/content/early/2021/11/11/2021.11.10.21266134.abstract
AB Background SARS-CoV-2 Delta variant has caused a dramatic resurgence in infections in the United Sates, raising questions regarding potential transmissibility among vaccinated individuals.Methods Between October 2020 and July 2021, we sequenced 4,439 SARS-CoV-2 full genomes, 23% of all known infections in Alachua County, Florida, including 109 vaccine breakthrough cases. Univariate and multivariate regression analyses were conducted to evaluate associations between viral load (VL) level and patient characteristics. Contact tracing and phylogenetic analysis were used to investigate direct transmissions involving vaccinated individuals.Results The majority of breakthrough sequences with lineage assignment were classified as Delta variants (74.6%) and occurred, on average, about three months (104 ± 57.5 days) after full vaccination, at the same time (June-July 2021) of Delta variant exponential spread within the county. Six Delta variant transmission pairs between fully vaccinated individuals were identified through contact tracing, three of which were confirmed by phylogenetic analysis. Delta breakthroughs exhibited broad VL values during acute infection (IQR 1.2 – 8.64 Log copies/ml), on average 38% lower than matched unvaccinated patients (3.29 – 10.81 Log copies/ml, p<0.00001). Nevertheless, 49-50% of all breakthroughs, and 56-60% of Delta-infected breakthroughs exhibited VL above the transmissibility threshold (4 Log copies/ml) irrespective of time post vaccination.Conclusions Delta infection transmissibility and general VL patterns in vaccinated individuals suggest limited levels of sterilizing immunity that need to be considered by public health policies. In particular, ongoing evaluation of vaccine boosters should address whether extra vaccine doses might curb breakthrough contribution to epidemic spread.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Stephany W. Holloway University of Florida Chair and by funds of the University of Florida Office of Research and Health Science Center with resources from the Interdisciplinary Center for Biotechnology Research Gene Expression Core (RRID:SCR_019145), NextGen Sequencing Core (RRID:SCR_019152) and Bioinformatics Core (RRID:SCR_019120). Funding for this work was also provided by National Science Foundation (NSF) - Division of Environmental Biology (DEB) award no. 2028221, The AIDS HealthCare Foundation Award No. OS00000633 and The Rockefeller Foundation Award 2021 HTH 012. The co-authors are thankful to Maureen Long for her critical reading of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved under the category of Public Health practice by the University of Florida Institutional Review Board (IRB) and the Florida Department of Health IRB.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors